NeoGenomics NEO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $745.97M+10.9% | $727.33M+10.1% | $709.16M+10.1% | $689.19M+9.7% | $672.36M+10.1% | ||
| $424.06M+13.2% | $413.04M+11.5% | $400.96M+10.2% | $386.55M+7.3% | $374.48M+5.4% | ||
| $321.91M+8.1% | $314.29M+8.3% | $308.21M+9.9% | $302.64M+13.0% | $297.88M+16.7% | ||
| 43.2%-1.1pp | 43.2%-0.7pp | 43.5%-0.1pp | 43.9%+1.3pp | 44.3%+2.5pp | ||
| $36.43M+8.0% | $37.08M+19.0% | $35.87M+18.3% | $34.86M+24.9% | $33.72M+22.5% | ||
| $93.15M+6.9% | $92.01M+8.7% | $90.9M+13.1% | $89.51M+15.4% | $87.11M+16.5% | ||
| $270.87M+3.3% | $273.34M+5.2% | $273.47M+6.9% | $270.57M+8.1% | $262.15M+6.0% | ||
| $428.21M+10.6% | $430.17M+12.6% | $429.08M+15.1% | $417.69M+15.0% | $387.24M+8.0% | ||
| $428.21M+10.6% | $430.17M+12.6% | $429.08M+15.1% | $417.69M+15.0% | $387.24M+8.0% | ||
| -$106.3M-18.9% | -$115.88M-25.8% | -$120.87M-31.0% | -$115.05M-20.8% | -$89.36M+13.4% | ||
| -14.2%-1.0pp | -15.9%-2.0pp | -17%-2.7pp | -16.7%-1.5pp | -13.3%+3.6pp | ||
| $2.73M-58.3% | $3.75M-43.3% | $4.78M-28.4% | $5.82M-13.4% | $6.55M-4.2% | ||
| $6.62M-61.8% | $9.07M-50.8% | $11.88M-37.3% | $14.99M-20.3% | $17.31M-6.5% | ||
| $219K+529% | $296K+178% | -$219K-224% | $433K+283% | -$51K-110% | ||
| -$102.19M-29.9% | -$110.27M-36.7% | -$113.99M-42.8% | -$105.45M-26.4% | -$78.65M+13.6% | ||
| -$2.98M-180% | -$2.24M-15.1% | -$522K+75.2% | -$1.41M+71.1% | -$1.06M+84.4% | ||
| -$99.21M-27.9% | -$108.03M-37.2% | -$113.47M-46.0% | -$104.04M-32.5% | -$77.59M+7.9% | ||
| -13.3%-1.8pp | -14.9%-2.9pp | -16%-3.9pp | -15.1%-2.6pp | -11.5%+2.3pp | ||
| -$0.76-24.6% | -$0.83-33.9% | -$0.88-44.3% | -$0.81-30.6% | -$0.61+7.6% | ||
| 513.6M+1.2% | 511.8M+1.1% | 510.4M+1.1% | 508.9M+1.0% | 507.4M+0.9% | ||
| 513.6M+1.2% | 511.8M+1.1% | 510.4M+1.1% | 508.9M+1.0% | 507.4M+0.9% | ||
| -$0.76-24.6% | -$0.83-33.9% | -$0.88-44.3% | -$0.81-30.6% | -$0.61+7.6% | ||
| -$0.76-24.6% | -$0.83-33.9% | -$0.88-44.3% | -$0.81-30.6% | -$0.61+7.6% | ||
| —— | $27.75M— | $20.81M— | $13.88M— | $6.94M— | ||
| $219K+529% | $296K+178% | -$219K-224% | $433K+283% | -$51K-110% | ||
| -$106.3M-18.9% | -$115.88M-25.8% | -$120.87M-31.0% | -$115.05M-20.8% | -$89.36M+13.4% | ||
| -$39.79M-129% | -$48.06M-146% | -$51.25M-162% | -$43.89M-95.8% | -$17.36M+42.6% | ||
| -$39.79M-129% | -$48.06M-146% | -$51.25M-162% | -$43.89M-95.8% | -$17.36M+42.6% | ||
| -5.3%-2.8pp | -6.6%-3.6pp | -7.2%-4.2pp | -6.4%-2.8pp | -2.6%+2.4pp | ||
| -$106.3M-18.9% | -$115.88M-25.8% | -$120.87M-31.0% | -$115.05M-20.8% | -$89.36M+13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NeoGenomics's revenue?
- NeoGenomics (NEO) generated $746.0M in revenue over the trailing twelve months, up 10.9% year over year.
- Is NeoGenomics profitable?
- NeoGenomics is not currently profitable: it reported a net loss of $99.2M over the trailing twelve months, a -13.3% net margin.
- What are NeoGenomics's profit margins?
- Gross margin is 43.2% and operating margin is -14.2%, with a -13.3% net margin.
- What is NeoGenomics's earnings per share?
- NeoGenomics's diluted EPS over the trailing twelve months is $-0.76.
- Where does NeoGenomics's income statement data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
